To determine the impact of Raptor/mTORC1 on tumor vasculature, we first assessed tumor microvessel density and morphology in situ using CD31 and smooth muscle actin (α-SMA), a pericyte marker, to visualize ECs in low-dose RAD001–treated LLC-HRE-mCherry-OVA tumors (Figure 3A). Here, RPTOR is linked to neoplasm.